Browse > Article

The Technological Concept of Fibroscan and its Clinical Usefulness in the Traditional Korean Medical Field  

Son, Chang-gue (Liver and Immunology Research Center, Oriental Medical College in Dae-Jeon University)
Publication Information
The Journal of Internal Korean Medicine / v.36, no.2, 2015 , pp. 85-92 More about this Journal
Abstract
Objectives: The liver fibroscan has been developed as a noninvasive and convenient method to assess hepatic fibrosis. This study aimed to review this device in terms of its technological concept and clinical application in traditional Korean medicine (TKM). Methods: The technological background, diagnostic evaluation, and clinical usefulness of fibroscan were reviewed using various literature and clinical studies. One clinical example-a patient with hepatofibrosis who had been treated with TKM-is presented. Results: The liver fibroscan was approved as a medical device for noninvasive measurement of the hepatic fibrosis level by the Korean Food and Drug Administration (KFDA). Numerous clinical studies have confirmed that its sensitivity and specificity allow it to serve as a substitute for liver biopsy, the present gold standard diagnostic method. The accuracy and reproducibility and lack of technical risks are strong points of the fibroscan; however, it has some limitations for application, especially in patients with obesity or severe hepatitis. One clinical example showed the applicability of the liver fibroscan in herbal medicine-based treatments. Conclusions: The requirement for diagnostic medical devices is an important issue in TKM; therefore, this study provides valuable information for practitioners of TKM.
Keywords
fibroscan; hepatic fibrosis; traditional Korean medicine;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Geramizadeh B, Janfeshan K, Saberfiroozi M. Serum hyaluronic acid as a noninvasive marker of hepatic fibrosis in chronic hepatitis B. Saudi J Gastroenterol 2008;14(4):174-7.   DOI
2 Bonder A, Afdhal N. Utilization of FibroScan in clinical practice. Curr Gastroenterol Rep 2014; 16(2):372.   DOI
3 Available at URL: http://www.mjmedi.com/news/articleView.html?idxno=28269
4 Available at URL: http://news.naver.com/main/read.nhn?mode=LSD&mid=sec&sid1=115&oid=057&aid=000004615
5 Schuppan D, Kim YO. Evolving therapies for liver fibrosis. J Clin Invest 2013;123(5):1887-901.   DOI
6 Yang L, Stimpson SA, Chen L, Wallace Harrington W, Rockey DC. Effectiveness of the PPARγ agonist, GW570, in liver fibrosis. Inflamm Res 2010;59(12):1061-71.   DOI
7 Sookoian S, Fernández MA, Castaño G. Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: a pilot study. World J Gastroenterol 2005;11(48):7560-3.   DOI
8 Friedman SL. Liver fibrosis -from bench to bedside. J Hepatol 2003;38 Suppl 1:S38-53.
9 Castera L, Bedossa P. How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography vs. liver biopsy? Liver Int 2011;31 Suppl 1:13-7.
10 Ding H, Wu T, Ma K, Wang X, Wu Z, Guo W, et al. Noninvasive measurement of liver fibrosis by transient elastography and influencing factors in patients with chronic hepatitis B-A single center retrospective study of 466 patients. J Huazhong Univ Sci Technolog Med Sci 2012;32(1):69-74.   DOI
11 Myers RP, Crotty P, Pomier-Layrargues G, Ma M, Urbanski SJ, Elkashab M. Prevalence, risk factors and causes of discordance in fibrosis staging by transient elastography and liver biopsy. Liver Int 2010;30(10):1471-80.   DOI
12 Ji D, Shao Q, Han P, Li F, Li B, Zang H, et al. The frequency and determinants of liver stiffness measurement failure: a retrospective study of “real-life” 38,464 examinations. PLoS One 2014; 9(8):e105183   DOI
13 Herrero JI, Iñarrairaegui M, D’Avola D, Sangro B, Prieto J, Quiroga J. Comparison of the M and XL FibroScan(®) probes to estimate liver stiffness by transient elastography. Gastroenterol Hepatol 2014;37(4):233-9.   DOI
14 Boursier J, Konaté A, Gorea G, Reaud S, Quemener E, Oberti F, Hubert-Fouchard I, Dib N, Calès P. Reproducibility of liver stiffness measurement by ultrasonographic elastometry. Clin Gastroenterol Hepatol 2008;6(11):1263-9.   DOI
15 Kim SU, Seo YS, Cheong JY, Kim MY, Kim JK, Um SH, et al. Factors that affect the diagnostic accuracy of liver fibrosis measurement by Fibroscan in patients with chronic hepatitis B. Aliment Pharmacol Ther 2010;32(3):498-505.   DOI
16 Wong VW, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2009;51(2):454-62.   DOI
17 Ginès P1, Cárdenas A, Arroyo V, Rodés J. Management of cirrhosis and ascites. N Engl J Med 2004;350(16):1646-54.   DOI
18 Cocciolillo S, Parruti G, Marzio L. CEUS and Fibroscan in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. World J Hepatol 2014;6(7):496-503.   DOI
19 Goyal R, Mallick SR, Mahanta M, Kedia S, Shalimar, Dhingra R, et al. Fibroscan can avoid liver biopsy in Indian patients with chronic hepatitis B. J Gastroenterol Hepatol 2013;28(11):1738-45.   DOI
20 Kim SU, Seo YS, Cheong JY, Kim MY, Kim JK, Um SH, et al. Factors that affect the diagnostic accuracy of liver fibrosis measurement by Fibroscan in patients with chronic hepatitis B. Aliment Pharmacol Ther 2010;32(3):498-505.   DOI
21 Nguyen-Khac E, Chatelain D, Tramier B, Decrombecque C, Robert B, Joly JP, et al Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests. Aliment Pharmacol Ther 2008;28(10):1188-98.   DOI
22 Theise ND. Liver biopsy assessment in chronic viral hepatitis: a personal, practical approach. Mod Pathol 2007;20 Suppl 1:S3-14.   DOI
23 Kim SU, Jang HW, Cheong JY, Kim JK, Lee MH, Kim DJ, et al. The usefulness of liver stiffness measurement using FibroScan in chronic hepatitis C in South Korea: a multicenter, prospective study. J Gastroenterol Hepatol 2011; 26(1):171-8.   DOI
24 Goertz RS, Egger C, Neurath MF, Strobel D. Impact of food intake, ultrasound transducer, breathing maneuvers and body position on acoustic radiation force impulse (ARFI) elastometry of the liver. Ultraschall Med 2012;33:380-5.   DOI
25 Popescu A, Bota S, Sporea I, Sirli R, Danila M, Racean S, et al. The influence of food intake on liver stiffness values assessed by acoustic radiation force impulse elastography-preliminary results. Ultrasound Med Biol 2013;39:579-84.   DOI
26 Pinzani M, Vizzutti F, Arena U, Marra F. Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. Nat Clin Pract Gastroenterol Hepatol 2008;5(2) :95-106.   DOI
27 Deffieux T, Gennisson JL, Bousquet L, Corouge M, Cosconea S, Amroun D, et al. Investigating liver stiffness and viscosity for fibrosis, steatosis and activity staging using Shear Wave Elastography. J Hepatol 2015;62(2):317-24.   DOI
28 Lee MH, Cheong JY, Um SH, Seo YS, Kim DJ, Hwang SG, et al. Comparison of surrogate serum markers and transient elastography (Fibroscan) for assessing cirrhosis in patients with chronic viral hepatitis. Dig Dis Sci 2010;55(12):3552-60.   DOI
29 Afdhal NH. Fibroscan (transient elastography) for the measurement of liver fibrosis. Gastroenterol Hepatol (NY). 2012;8(9):605-7.
30 Kemp W, Roberts S. FibroScan® and transient elastography. Aust Fam Physician 2013;42(7) :468-71.
31 Sandrin L, Cassereau D, Fink M. The role of the coupling term in transient elastography. J Acoust Soc Am 2004;115(1):73-83.   DOI
32 Rack CB, Cho HJ, Oh JT, Lee EK, Heo J, Shin KY, et al, Clinical factors influencing liver stiffness as measured by transient elastography (Fibroscan®) in patients with chronic liver disease. Korean J Hepato 2010;16(2):123-30.   DOI
33 Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 2007;102(11):2589-600.   DOI
34 Boursier J, de Ledinghen V, Zarski JP, Rousselet MC, Sturm N, Foucher J, et al. A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C. Am J Gastroenterol 2011; 106(7):1255-63.   DOI
35 Bravo AA, Sheth SG and Chopra S. Liver biopsy. N Engl J Med 2001;344(7):495-500.   DOI
36 Trifan A, Stanciu C. Checkmate to liver biopsy in chronic hepatitis C? World J Gastroenterol 2012;18(39):5514-20.   DOI
37 Kim H, Shin AR, Chung HH, Kim MK, Lee JS, Shim JJ, et al. Recent trends in hepatitis B virus infection in the general Korean population. Korean J Intern Med 2013;28(4):413-9.   DOI   ScienceOn
38 Kocabayoglu P, Friedman SL. Cellular basis of hepatic fibrosis and its role in inflammation and cancer. Front Biosci (Schol Ed) 2013;5:217-30.
39 Schmeltzer PA, Talwalkar JA. Noninvasive tools to assess hepatic fibrosis: ready for prime time? Gastroenterol Clin North Am 2011;40(3):507-21.   DOI
40 Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38(6):1449-57.   DOI
41 Papastergiou V, Tsochatzis E, Burroughs AK. Non-invasive assessment of liver fibrosis. Ann Gastroenterol 2012;25(3):218-31.
42 Wong GL. Update of liver fibrosis and steatosis with transient elastography (Fibroscan). Gastroenterol Rep (Oxf). 2013;1(1):19-26.   DOI